Member Info for The_Paladin

Returning to next week’s J.P. Morgan Annual Healthcare Conference. I found the reference to a Synairgen connection to the conference on a twitter investment tips thread. I failed to discover anything more substantial elsewhere.

The question arises as to why an agreement between a major pharmaceutical company and Synairgen would need to be announced next week at this event? Should there be a deal in place, why wait until next week? Time is precious for Synairgen. It has taken in excess of ten months for them to tidy up the failure underpinning the post-Sprinter share price collapse. Someone correctly stated yesterday that we haven’t received a single piece of news to restore market confidence since then.

The specialists’ contribution on this forum have often lauded the strong evidence fully justifying the potential of SNG001. The conversation is also swinging back to a potentially threatening Omricon variant. IMHO the current Covid ship may well have sailed. However the future pandemic preparation, and broad spectrum antiviral treatment markets are there as a basis for negotiation.

The company has a mere seven weeks to get a deal over the line before the 12-month high in the share price is at 35p. The spade work has been completed, and the recent publicity has been helpful. It is now time for Richard Marsden and his executives to finish their work.

GLA.

This is the same conference that Beforegolf mentioned, when he expressed his opinion that there was a likelihood of an improvement in outlook for Synairgen this year.

Unfortunately, there is no way of knowing whether Synairgen is presenting at the conference ? That information is only known to delegates. It is mentioned on the conference website that investors may have access to a company’s presentation via their website.

First, and foremost. I wish all Synairgen LTIs a happy and healthy New Year.

My second wish is that the doomsday scenarios suggested by doubters and embittered former investors, who currently harbour ill will towards the company, do not materialise this year.

Synairgen have until Shrove Tuesday, around seven weeks, to calm investors' worst fears. An invitation to participate in a P3 equivalent paid-for trial is best arranged before the anniversary of the Sprinter top line data RNS. Although it could well arrive after that date, and ameliorate our situation, all long term investors would prefer to receive the anticipated news in good time.

The company have drawn a line under the Sprinter trial with the publication of a peer-reviewed paper just before Christmas. Prior to that, the trial data and its analysis was widely disseminated during presentations at appropriate conferences, and through other agencies such as appropriate social media. Any interested party including large pharmaceutical companies will no doubt be well aware about what has been revealed about SNG001 through analysed trial data by now. They will have had the necessary time to ascertain the potential of SNG001 in their respective pipelines.

Post Feb 21, the 12 month high share price will reduce to 35p, and with it the possible price that interested BP companies would consider offering for the company in any emerging T/O scenario. Should that point be reached, the Synairgen board will probably consider all available options, and decide the best course of action, including a cash raise for another p3 trial.

I would prefer that we reach Feb 21, with a trial invitation firmly in place. The company have succeeded in widely disseminating the necessary information to highlight SNG001's qualities to potentially interested parties in recent months. They need to follow this up rapidly with a trial in place in the coming weeks to ensure that we are not caught up in a difficult situation from next March onwards.

GLA.

Not one of “my sources”, as you put it, Fruitsnveg. The diametric opposite! I have deleted the link to that forum, and will neither read it nor will I contribute to it in future. There is nothing useful to be gained from it IMHO.

As for Richard Marsden, I wish him well for the coming year. It is to our advantage that he is at the height of his powers for the important work that lies ahead. Whatever course he chooses for the company, we will need him to be at the top of his game. As for your alternative speculation, that thought crossed my mind. Would that it were true?

From studying the SNG information above, the share price has fallen from a year high of 212p last January to a year low of 11p on Dec 23. This is a drop of 94.8%.

Since the cause of the share price destruction on Feb 21, the company has backed off from that scenario, and wisely IMHO, picked up all the loose threads. Every piece of data has been rigorously analysed, categorised and disseminated, both in RNS format, and through presentations at international conferences. Just before Christmas, a firm line was drawn under the Sprinter trial with the release of a comprehensive account of the trial, which ends by identifying the future potential of SNG001. Synairgen have informed investors of their current strategy, and we are currently awaiting the outcome of their conversations with various potential collaborators?

As a beleaguered LTI, I see us with our backs to the wall. The small stuff, which has improved our negotiating position is complete. It is now time for the company to push forward.

There are three options as I see it.
1. A collaboration with an external provider in a trial .
2. A fund raise to manage our own trial.
3. A cheap buy out. This might enable investors to recoup our losses, but is likely to be well below the potential value of SNG001, which could be a valuable addition to any BP’s pipeline.

Someone on another forum (which I have stopped using due to the extreme negativity of some contributors) stated that Richard Marsden is currently enjoying a yachting break in the Florida Keys. If this is true, I wish him well, and hope that he returns refreshed and full of vigour. The company has sweated the necessary small stuff all year. The time is now ripe for Synairgen to push forward and get the important work done. GLA.

Correction. A report on the Lancet publication at an appropriate level to enable my full understanding.

Here is the publication. Well worth a read.

https://www.medscape.co.uk/viewarticle/molnupiravir-reduces-recovery-time-not-covid-19-2022a1002956?uac=457956CZ&faf=1&sso=true&impID=5022785&src=WNL_ukmdpls_221224_mscpedit_gen

Many thanks gunto2022 for supplying the link to Dr. Monk’s summary paper of the outcome of the Sprinter trial. It is a good time to release this document following several months of presentations of the data at appropriate conferences and gatherings. The subsequent release of the peer review will enable a line to be drawn under the study.

Long term investors, like myself, anticipate that the Herculean effort from the Synairgen scientists will bear fruit early on next year. Personally, I believe that TFG Asset Management will have a major part to play in what follows next. However, I have no idea about their strategy, or the time scale of its execution? Additionally, I have little idea whether we will be successful in achieving a trial through a PT invitation or through the JV route? Surely, Synairgen won’t need to resort to another capital raise through issuing more shares in order to fund the much needed trial? The extensive spadework completed this year fully justifies further trialling, but the need for a trial funded through issuing more shares would be viewed as a failure for Richard Marsden and his executives?

The future of SNG001, as I see it is two fold. First as a broad spectrum antiviral treatment, and secondly in preparing for the emergence of future pandemics. The hurdle of future trialling must be overcome before either of these objectives can be achieved. There may well be a long wait ahead for Synairgen long term investors before a return on our investors can be achieved?

Finally, having just read Doc.Daneeka’s recent post, I wish to extend my very best wishes to his parents as they continue to recover from their recent encounter with Covid. You must be very proud of the fortitude they have shown at difficult times Doc.
To conclude, my best wishes at Christmas to all Synairgen investors (especially LTIs). I hope that you will all enjoy a very special time with family and friends, and that there will be better times (investment wise) to follow in the coming New Year.

Thank you Brand and gunto2020 for the information updates. I failed to find the Quality Director update on LinkedIn, and will look again when I have the time.

It would seem, as I have always suspected, that the first major development, following all the spadework that has been successfully completed this year, will emerge from the USA? The way in which Synairgen’s very informative website is laid out, recent company activities, and the emerging US background information strongly suggests this.

I shan’t purchase any more shares, even at today’s tempting prices. I have more than sufficient to secure a good profit should the share price recover to 100p or greater.? Should that situation emerge, I will need to think carefully about what to do next? It has been a very tough year, for sure, but the company is well situated for a recovery, early in 2023 IMHO.

GLA.

Every comment and article that I have read about Imaging Biometrics is positive. I fail to understand, why the share price remains at the current level? Surely the company is significantly undervalued at today’s price?

I intend to hold all my shares for the foreseeable future. I might be tempted to sell if there is a small profit on offer ? This is because the company is poorly managed at the directorate level in my view. If the information from IB is as sound as it reads, all will be well in due time. Bearing in mind the miserable decline that the share price has undergone this year, who knows when the share price will start to pick up ? It will take a significant catalyst to get it moving, for sure.

GLA.

Thank you for sharing Doc83. I was thinking along the same lines, but the possibility of a leak hadn’t occurred to me.

Like you , my confidence in SNG001 is holding firm. As I commented yesterday, the company have sweated the small stuff all year. Most of it has been necessary , but the share price has eroded to less than half the maximum price achieved since Feb 28. It is now high time for them to get the real work done. When the results of successful negotiations for a suitable trial are announced, confidence in the company will be restored, and the share price decline will reverse. One can hope that this will happen sooner rather than later?

It has been a tough year for LTIs, and much remains for the company to do.

ATB and GLA.

Doc83. Your contributions to this forum suggest otherwise. One year ago, your “£10 or 10p” prediction has turned out to be the sanest comment I have read on this forum.

The company had more than enough investor capital at its disposal to take SNG001 through a successful trial during a severe pandemic. They failed. Why would any investor want to fund another trial?

If the Synairgen team are as good as we believed them to be a year ago, they should be able to negotiate a place on another trial through either the PT or the JV route. That remains to be seen?

I still haven’t worked out what caused the abrupt share price decline during the last half hour of trading today?

Once the share price dropped to 14.8p, there was a flurry of trading which mostly show up as buys, though one is never sure? This is contrary to my expectations , but what do I understand?

The facts are simple. Since the failed trial last February the company has been active, but all its activity has been funded by the residue of the capital remaining from the trial placement? Despite encouraging results from further trial analysis, the company has apparently made little progress in progressing towards a new trial invitation? Investors have been presented with an outline strategy, but no concrete indication that we are progressing towards a trial?

Tomorrow is another day. Until I have an explanation for today’s severe late drop in share price, I won’t give the matter too much thought.

For sure, no sane investor is going to back the Synairgen team in a fund raise for another trial. Richard Marsden has a talent for recklessly spending investor’s money, but has yet to prove that he and his team have the ability to bring their product to market, and generate income commensurate with the level of investment that his company has received in recent years.

GLA.

https://tools.morningstar.co.uk/uk/stockreport/default.aspx?tab=0&vw=st&SecurityToken=0P00007OXV%5D3%5D0%5DE0WWE%24%24ALL&Id=0P00007OXV&ClientFund=0&CurrencyId=BAS

Excellent contribution Trinityman.

It sums up our current situation. The company have indeed “worked hard” to ameliorate the effect of last February’s disappointing announcement.

All existing data has been analysed, evaluated, and presented at major industry specific conferences. Recently a relevant discussion, hosted by Scientific American, was funded by the company. Two informative podcasts were produced by a the company. I could go on.

All this hard work is what some US business people would call sweating the small stuff. All were essential to draw attention to the important role that SNG001 could play in the future, but the share price has continued to decline significantly despite the company’s considerable effort.

I remain optimistic that there will be a way forward, whether through a platform trial, or in collaboration with a large pharmaceutical company perhaps ? Ideally, I would prefer a buyout at a fair price to all investors. Many will disagree with that view.

Unfortunately, all of us who remain invested have to continue living with uncertainty for the time being. Next year we might all be millionaires?

ATB and GLA.

Here is the article related to that comment.

https://healthimaging.com/topics/medical-imaging/computed-tomography-ct/cancer-risk-pediatric-head-cts

I have changed the thread title, as the previous thread originated from a green box. Consequently, I have no wish to read its source.

Mostly good points Manifesto. Most LTI's future aspirations are pinned on these. With my nit picker's hat firmly in place, I would, however, question two of those points:

Point 3. Is there any evidence that Synairgen were "invited" to present at an US conference? IMHO the company paid for all the speaking opportunities, as laid out in the prospectuses of the conference organisers? It would appear that the company paid for a consultant (Dr. Mark Main) to accompany at least four Synairgen representatives to one of the presentations. Last week, Synairgen funded a Scientific American led discussion on broad spectrum anti viral therapies with the notable addition of two keynote attendees in addition to Dr. Monk. All of these were necessary, in my view, in order for the company to realise its objectives. However, I doubt whether Synairgen was invited to attend any of them?

Point 7. I hope that you are right about this. We know from the last feedback on the cash position that Synairgen had sufficient funding to remain afloat at least until late Summer 2023. This seems quite a while away. However it is an equivalent time frame to the one from the AGM to the present time.

In a post yesterday, I questioned Richard Marsden's hiring of various SVPs "at haste" prior to the Sprinter top line data announcement. As a consequence, these executives' salaries are adding considerably to Synairgen's cash burn. They are unable to participate in the roles for which they were hired. What then are they being paid for? It is obvious that Brooke Clarke is active in her role. However, she is currently limited to updating investors and others about upcoming presentation events, and subsequently in providing limited feedback. She has also been given the bare bones of a strategy to reply to all investors' online queries. Brooke Clarke aside, what are Dr. Gareth Walters, Helen Gearing, Richard Hennings, and Richard Francis doing to justify their salaries? Why did Richard Marsden hire an SVP Head of Finance before it was necessary? Wasn't a CFO sufficient to complete the financial necessities of a relatively dormant company?
None of the above executives are to blame for this. Had there been a better outcome last February, their undoubted abilities and experience would now be applied to the betterment of the company. However, I fail to see how they can justify their roles at present?
Sadly this leads me to question Richard Marsden's judgement? He acted hastily with expensive hires before the outcome of the Sprinter trial was announced? We have no evidence yet to confirm that ten months of considerable effort, especially from the company's scientists, has led to the outcome that investors have been anticipating for a considerable time?

I sincerely hope that your optimism, as well as my own, are fulfilled Manifesto. GLA.

I have been bullish about Synairgen's future for most of the current year, apart from six weeks or so following the Sprinter topline data RNS. The reasons for being optimistic are given in RNS statements over the last thirty months or so. However, the current situation should not be allowed to prevail for much longer. The share price is currently around 200p lower than it was towards the end of 2021. It is eroding on a daily basis, as investors continue to wait for news of a trial invitation.

Surely Richard Marsden should not be allowed to carry on for much longer without making structural changes to the company? Currently there are a significant number of SVPs ,drawing appropriate salaries for those roles, without being able to fulfil them as originally intended? Those roles will be necessary following a successful P3 trial. As an investor, it would be useful to know how their time with the company is currently being deployed? When we read about more junior appointments recently, I was optimistic about receiving some imminent positive news? Sadly there has been nothing appear from an outline strategy, which any investor could have written themselves?

IMHO, Richard Marsden needs to take some hard decisions. He was like a kid with extra pocket money in a sweetshop leading up to last February. He hired appropriately in advance of a successful trial outcome. His capital was derived from investors' additional funding, at 175p per share, in support of the Sprinter trial? Perhaps he should have been more cautious?

All that is water well under the bridge. I have nothing negative to write about any of the Synaigen executives. Their records show that they were all appropriate hires for a THRIVING company. However, how long is this death by a thousand cuts of the share price going to endure, without positive news, or at least restructuring of the companyas a consequence of the lack of success?

I don't apologise for writing as though I was MrCosts' long lost twin? He is rightly concerned about the current situation, as should all LTIs be. I would welcome any positive update from the company which would show my "rant" to be an over -reaction. More to the point, I believe that the company has done very well, Dr Monk in particular, in disseminating the right information to attract attention from a large pharmaceutical company. There may be a reason why nothing has yet happened? I also think that investors deserve more information than the bare bones of a strategy that Brooke Clarke has been given to disseminate as a response to all investors' enquiries?

GLA.

Thank you Titania for keeping a relevant converstion in flow. The silence from Synairgen regarding a potential trial for SNG001 is puzzling IMHO? I was optimistic of such news arriving last week to coincide with the Scientific American led discussion, but nothing has yet materialised? I cannot now see a big announcement coming until at least the start of the New Year? It would be good to be proven to be incorrect about this.

Meanwhile, in the absence of news, our top posters are discussing food banks, Elon Musk, and AI. All very interesting, but with Winter having well and truly gripped the country, most investors were all hoping for something concrete by now. At least no one here wants to defenestrate Richard Marsden, as was the case on the advfn board this morning. GLA

Thank you gunto2022. As I have stated previously, the Synairgen Comms team are doing a first rate job. This is very informative, and encouraging for LTIs following a difficult year. Onwards and upwards from here, as I see it. My opinion only. DYOR etc.

This week's event was informative, but has not led to the market response that all long term investors were hoping for. Nevertheless, we have seen over one percent of the company's shares traded in a single day since then. I lack the understanding to interpret the significance of that trading flurry? It is unlikely that anything will happen in the days leading up to Christmas? However my optimism remains intact for the coming year. GLA.